Based on the provided sources, there is no specific information available regarding the potential for lurbinectedin to cause birth abnormalities. The sources primarily focus on providing general information about lurbinectedin, its patent status, and its use in cancer treatment. There is no mention of any reported cases or studies specifically addressing the risk of birth abnormalities associated with lurbinectedin.

To obtain more accurate and detailed information about the potential risks of lurbinectedin during pregnancy, it is recommended to consult healthcare professionals or refer to other reliable sources such as medical journals or the prescribing information provided by the manufacturer.

Sources:
[1] Drug Patent Watch. "Lurbinectedin." Available at: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Cancer Institute. "Cancer Terms: Lurbinectedin." Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms
[3] U.S. Food and Drug Administration. "Lurbinectedin (Zepzelca) Prescribing Information." Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf